Recombinant Tissue Plasminogen Activator (rtPA) for Stroke: The Perspective at 8 Years

Objective:To review the 8-year experience with recombinant tissue plasminogen activator (rtPA) for stroke, with commentary on ramifications for the approach to stroke treatment, directions in stroke research, and sociological aspects of stroke as a disease of concern in our society. Background:Approved in 1996, rtPA remains the only drug indicated for the treatment of ischemic stroke. Stroke treatment and research have evolved rapidly in response to opportunities and discoveries related to the advent of rtPA. The presence of rtPA has engendered an increased level of awareness about all aspects of stroke. Methodology:Literature review was performed, focusing on topics that in the author's view are of greatest relevance to the use of rtPA in clinical practice and to the directions in which the presence of rtPA is moving the field of stroke treatment, research, and politics. Results:Challenges have been raised, and met, regarding the validity of the data upon which the approval for rtPA was based. Limitations in the use of rtPA include the brief time available for treatment, the need for rapid imaging and blood-pressure control, and the fact that large-artery occlusions respond poorly. The major risk of treatment is brain hemorrhage, and although predictors of hemorrhage are known, their presence does not constitute an absolute contraindication to treatment. A virtual subindustry has evolved to enhance the benefit and applicability of rtPA through refined imaging technology and the use of rtPA intra-aterially, as well as in combination with other agents and devices. Sociopolitically, rtPA has elevated the level of awareness of stroke and provided impetus for the stroke center movement and federal legislation to stop stroke. Conclusion:The development of rtPA has been the most effective advance in the field of stroke. It has generated healthy debate regarding the design, performance, and interpretation of stroke trials, including cost-benefit considerations. rtPA has stimulated research in a multitude of areas, enhanced our understanding of stroke pathophysiology, and defined important limits and risks for urgent intervention. rtPA is the cornerstone of the stroke center movement, as well as legislation in behalf of stroke at the congressional level.

[1]  Ims Study Investigators.  Hemorrhage in the Interventional Management of Stroke Study , 2006, Stroke.

[2]  R. Spetzler,et al.  Cavernous Malformation of the Trigeminal Nerve Manifesting with Trigeminal Neuralgia: Case Report , 2005, Neurosurgery.

[3]  M. Flaster,et al.  tPA by telephone: Extending the benefits of a comprehensive stroke center , 2005, Neurology.

[4]  R. Spetzler,et al.  Intra-arterial Thrombolysis for Acute Ischemic Stroke: Preliminary Experience with Platelet Glycoprotein IIb/IIIa Inhibitors as Adjunctive Therapy , 2005, Neurosurgery.

[5]  A. Alexandrov,et al.  Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. , 2004, The New England journal of medicine.

[6]  S. Pedraza,et al.  The clinical–DWI mismatch , 2004, Neurology.

[7]  D. Matchar.  Editorial comment--what can models teach us about stroke treatment? Sorting out the missing bits. , 2004, Stroke.

[8]  D. Krieger,et al.  Therapeutic Hypothermia for Acute Ischemic Stroke: What Do Laboratory Studies Teach Us? , 2004, Stroke.

[9]  Jeffrey L. Saver,et al.  Prehospital Neuroprotective Therapy for Acute Stroke: Results of the Field Administration of Stroke Therapy–Magnesium (FAST–MAG) Pilot Trial , 2004, Stroke.

[10]  Alexander Norbash,et al.  Mechanical Thrombolysis in Acute Ischemic Stroke With Endovascular Photoacoustic Recanalization , 2004, Stroke.

[11]  G. Rollins.  Combined stroke trial data confirms that early treatment with thrombolytics improves outcomes. , 2004, Report on medical guidelines & outcomes research.

[12]  Ims Study Investigators.  Combined Intravenous and Intra-Arterial Recanalization for Acute Ischemic Stroke: The Interventional Management of Stroke Study , 2004, Stroke.

[13]  Scott Hamilton,et al.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.

[14]  M. Diringer,et al.  Treatment of fever in the neurologic intensive care unit with a catheter-based heat exchange system , 2004, Critical care medicine.

[15]  N. Poungvarin.  Steroids have no role in stroke therapy. , 2003, Stroke.

[16]  J. Norris.  Steroids may have a role in stroke therapy. , 2003, Stroke.

[17]  G. Donnan,et al.  Steroids for stroke: another potential therapy discarded prematurely? , 2003, Stroke.

[18]  Zhenggang Zhang,et al.  Treatment of acute stroke with recombinant tissue plasminogen activator and abciximab. , 2003, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[19]  G. D. Graham,et al.  Tissue Plasminogen Activator for Acute Ischemic Stroke in Clinical Practice: A Meta-Analysis of Safety Data , 2003, Stroke.

[20]  J. Hoffman.  Tissue plasminogen activator (tPA) for acute ischaemic stroke: why so much has been made of so little , 2003, The Medical journal of Australia.

[21]  K. Arai,et al.  Lipoprotein receptor–mediated induction of matrix metalloproteinase by tissue plasminogen activator , 2003, Nature Medicine.

[22]  J. Koziol,et al.  Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. , 2003, Stroke.

[23]  R. Seitz,et al.  Thrombolysis With Recombinant Tissue Plasminogen Activator and Tirofiban in Stroke: Preliminary Observations , 2003, Stroke.

[24]  Richard Frayne,et al.  Reliability of Assessing Percentage of Diffusion-Perfusion Mismatch , 2003, Stroke.

[25]  M. Chopp,et al.  Adjuvant Treatment With a Glycoprotein IIb/IIIa Receptor Inhibitor Increases the Therapeutic Window for Low-Dose Tissue Plasminogen Activator Administration in a Rat Model of Embolic Stroke , 2003, Circulation.

[26]  Fernando Vinuela,et al.  Beyond tissue plasminogen activator: mechanical intervention in acute stroke. , 2003, Annals of emergency medicine.

[27]  D. Summers,et al.  Expanded Modes of Tissue Plasminogen Activator Delivery in a Comprehensive Stroke Center Increases Regional Acute Stroke Interventions , 2003, Stroke.

[28]  Jeffry R Alger,et al.  Perfusion-Weighted Magnetic Resonance Imaging Thresholds Identifying Core, Irreversibly Infarcted Tissue , 2003, Stroke.

[29]  Kyung-Yul Lee,et al.  Increase in Plasma Matrix Metalloproteinase-9 in Acute Stroke Patients With Thrombolysis Failure , 2003, Stroke.

[30]  A. Demchuk,et al.  Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke , 2003, Neurology.

[31]  W. Burgin,et al.  Pilot Dose-Escalation Study of Caffeine Plus Ethanol (Caffeinol) in Acute Ischemic Stroke , 2003, Stroke.

[32]  B. Bledsoe.  EMS mythology. EMS myth #2. Thombolytic therapy is the standard of care for acute ischemic stroke. , 2003, Emergency medical services.

[33]  H. Jahnke.  An 89-year-old woman with angioedema during t-PA infusion for acute ischemic stroke. , 2003, Journal of emergency nursing: JEN : official publication of the Emergency Department Nurses Association.

[34]  R. Grubb,et al.  Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association , 2003, Stroke.

[35]  P. Hu,et al.  Telemedicine for Acute Stroke: Triumphs and Pitfalls , 2003, Stroke.

[36]  J. Arenillas,et al.  Matrix Metalloproteinase-9 Pretreatment Level Predicts Intracranial Hemorrhagic Complications After Thrombolysis in Human Stroke , 2003, Circulation.

[37]  D. Kent,et al.  Are Some Patients Likely to Benefit From Recombinant Tissue-Type Plasminogen Activator for Acute Ischemic Stroke Even Beyond 3 Hours From Symptom Onset? , 2003, Stroke.

[38]  Werner Hacke,et al.  Imaging-Based Decision Making in Thrombolytic Therapy for Ischemic Stroke: Present Status , 2003, Stroke.

[39]  M. LaMonte,et al.  Triumphs and Pitfalls , 2003 .

[40]  E. Lo,et al.  Blood-Brain Barrier Disruption and Matrix Metalloproteinase-9 Expression During Reperfusion Injury: Mechanical Versus Embolic Focal Ischemia in Spontaneously Hypertensive Rats , 2002, Stroke.

[41]  Reciprocal actions of NCAM and tPA via a Ras-dependent MAPK activation in rat hippocampal neurons. , 2002, Biochemical and biophysical research communications.

[42]  A. Demchuk,et al.  Safety of Tissue Plasminogen Activator for Acute Stroke in Menstruating Women , 2002, Stroke.

[43]  E. Lo,et al.  Extracellular proteolysis in brain injury and inflammation: Role for plasminogen activators and matrix metalloproteinases , 2002, Journal of neuroscience research.

[44]  C. Siao,et al.  Tissue Plasminogen Activator Mediates Microglial Activation via Its Finger Domain through Annexin II , 2002, The Journal of Neuroscience.

[45]  G. Thomalla,et al.  Acute Basilar Artery Occlusion Treated With Combined Intravenous Abciximab and Intra-arterial Tissue Plasminogen Activator: Report of 3 Cases , 2002, Stroke.

[46]  Jean-Philippe Thiran,et al.  Prognostic accuracy of cerebral blood flow measurement by perfusion computed tomography, at the time of emergency room admission, in acute stroke patients , 2002, Annals of neurology.

[47]  J. Lenzer.  Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign. , 2002, BMJ : British Medical Journal.

[48]  P. Vespa,et al.  Predictors of Hemorrhagic Transformation in Patients Receiving Intra-Arterial Thrombolysis , 2002, Stroke.

[49]  E. Lo,et al.  Involvement of Matrix Metalloproteinase in Thrombolysis-Associated Hemorrhagic Transformation After Embolic Focal Ischemia in Rats , 2002, Stroke.

[50]  G. Albers,et al.  ATLANTIS Trial: Results for Patients Treated Within 3 Hours of Stroke Onset , 2002, Stroke.

[51]  Stephen Rose,et al.  Diffusion‐ and perfusion‐weighted MRI response to thrombolysis in stroke , 2002, Annals of neurology.

[52]  A. Alexandrov,et al.  Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. , 2001, Archives of neurology.

[53]  M. Lawton,et al.  C-Reactive Protein Levels and Viable Chlamydia pneumoniae in Carotid Artery Atherosclerosis , 2001, Stroke.

[54]  J. Grotta.  Combination Therapy Stroke Trial: Recombinant Tissue-Type Plasminogen Activator with/without Lubeluzole , 2001, Cerebrovascular Diseases.

[55]  Thrombolytic therapy for acute ischemic stroke - Tissue plasminogen activator for acute ischemic stroke: Is the CAEP Position Statement too negative? , 2001, CJEM.

[56]  Andrew N. Brown,et al.  Utilization of Intravenous Tissue-Type Plasminogen Activator for Ischemic Stroke at Academic Medical Centers: The Influence of Ethnicity , 2001, Stroke.

[57]  Alain Buisson,et al.  The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling , 2001, Nature Medicine.

[58]  J. Hoffman.  Should physicians give tPA to patients with acute ischemic stroke? Against: and just what is the emperor of stroke wearing? , 2000, The Western journal of medicine.

[59]  R E Latchaw,et al.  Recommendations for the establishment of primary stroke centers , 2000 .

[60]  M E Moseley,et al.  New magnetic resonance imaging methods for cerebrovascular disease: Emerging clinical applications , 2000, Annals of neurology.

[61]  S Hamilton,et al.  The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. , 2000, Stroke.

[62]  D. Blacker,et al.  High rate of complete recanalization and dramatic clinical recovery during tPA infusion when continuously monitored with 2-MHz transcranial Doppler monitoring. , 2000, Stroke.

[63]  J. Milbrandt,et al.  Treating acute stroke patients with intravenous tPA. The OSF stroke network experience. , 2000, Stroke.

[64]  A. Alexandrov,et al.  High rate of complete recanalization and dramatic clinical recovery during tPA infusion when continuously monitored with 2-MHz transcranial doppler monitoring. , 2000, Stroke.

[65]  R. Higashida,et al.  Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial , 1999 .

[66]  J. Grotta,et al.  Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. , 1999, Stroke.

[67]  G. Schlaug,et al.  The ischemic penumbra: operationally defined by diffusion and perfusion MRI. , 1999, Neurology.

[68]  J. Riggs.  Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. , 1999, Neurology.

[69]  M. Kaste,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.

[70]  G. Rosenberg,et al.  Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. , 1998, Stroke.

[71]  M Frankel,et al.  Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke , 1998, Neurology.

[72]  G. Hankey,et al.  Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. , 1996, JAMA.

[73]  M. Hommel,et al.  Thrombolytic therapy with streptokinase in acute ischemic stroke. , 1996, The New England journal of medicine.

[74]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[75]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[76]  L. Munari,et al.  RANDOMIZED CONTROLLED TRIAL OF STREPTOKINASE, ASPIRIN, AND COMBINATION OF BOTH IN TREATMENT OF ACUTE ISCHEMIC STROKE , 1995 .

[77]  Multicentre Acute Stroke Trial—Italy Group.  Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke , 1995, The Lancet.

[78]  R. Califf,et al.  Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. , 1995, Journal of the American College of Cardiology.

[79]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.

[80]  R. Spetzler,et al.  Intrathrombus Administration of Tissue Plasminogen Activator in Acute Cerebrovascular Occlusion , 1995, Angiology.

[81]  P. Toutouzas,et al.  Percutaneous implantation of autologous vein graft stent for treatment of coronary artery disease , 1995, The Lancet.

[82]  T. Lee,et al.  Cost effectiveness of tissue plasminogen activator. , 1995, The New England journal of medicine.

[83]  W. Hacke,et al.  Local intra-arterial fibrinolytic therapy in acute carotid territory stroke. A pilot study. , 1988, Stroke.

[84]  H. Zeumer,et al.  Thrombolytic therapy in stroke: possibilities and hazards. , 1986, Stroke.

[85]  E. Ringelstein,et al.  Local intraarterial thrombolysis in vertebrobasilar thromboembolic disease. , 1983, AJNR. American journal of neuroradiology.

[86]  M. Scully,et al.  Thrombolytic therapy. , 1968, British medical bulletin.

[87]  E. O. Bregman,et al.  The Present Status. , 1926 .

[88]  S. Jasko,et al.  Therapy , 1881, The American journal of dental science.